Sarepta Stock

Investors Excited About Sarepta Earnings Report Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) are on fire ever since earnings came out on Wednesday, July 19. Investors are clearly excited about the company’s potential. They even celebrated by sending Sarepta stock price up more than 20%. “What’s got them…

SRPT Stock: Staying True to my Word, a Bullish View Is Once Again Warranted Sarepta Therapeutics Inc (NASDAQ:SRPT) stock reported earnings on July 19, and it caused SRPT stock to spike by 20.1% the following day, closing the day's trading at $40.93. This closing price is why I am…

SRPT Stock: Allegations Are Taking Center Stage Wow, there is quite a fiasco brewing around Sarepta Therapeutics Inc (NASDAQ:SRPT) stock, and the allegations alone are reason enough to rethink a potential investment in SRPT stock. There are allegations swirling around Sarepta suggesting that its “Eteplirsen” drug that treats Duchenne…

SRPT Stock: Awaiting a Resolution Sarepta Therapeutics Inc (NASDAQ:SRPT) stock isn't your average investment. This trading vehicle is known for its wild price swings. On September 19, 2016, Sarepta stock soared by 73.8% in a single day after it finally received Food and Drug Administration (FDA) approval for…

SRPT Stock: Price Shocks Sarepta Therapeutics Inc (NASDAQ:SRPT) stock soared on January 10, 2017 following its presentation at the JPMorgan Healthcare Conference. That's where Sarepta announced that the company’s Duchenne muscular dystrophy (DMD) drug—which was just approved by the U.S. Food and Drug Administration (FDA) in September 2016—generated $5.4…

SRPT Stock: Support Found Here Sarepta Therapeutics Inc (NASDAQ:SRPT) stock is not for the faint of heart. The volatility that accompanies SRPT stock is just incredible. What other company can boast being down 79% year-to-date, only to reverse this tremendous loss and post a positive return of 65%…